Advanced Nanotechnology-Based Nucleic Acid Medicines.

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Nanomedicine
• Molecular Therapeutics

Background:

• Nucleic acid medicines offer sequence-specific targeting of molecules.
• 21 nucleic acid medicines are approved by the FDA.
• Challenges remain in tissue targeting and intracellular delivery.

Purpose of the Study:

• To review the latest advancements in nanotechnology for nucleic acid medicines.
• To summarize the status of clinical trials for nanotechnology-based nucleic acid medicines in Japan.
• To discuss future expectations for this therapeutic modality.

Main Methods:

• Literature review of recent research in nanotechnology applied to nucleic acid medicines.
• Analysis of clinical trial data for nanotechnology-based nucleic acid medicines, with a focus on Japan.
• Synthesis of current trends and future prospects.

Main Results:

• Over 40 nanotechnology-based nucleic acid medicines have entered clinical trials outside Japan, with 15 currently active.
• Three Phase I clinical trials involving nanotechnology-based nucleic acid medicines are ongoing in Japan.
• Nanotechnology is actively being employed to overcome delivery and targeting challenges.

Conclusions:

• Nanotechnology is crucial for advancing nucleic acid medicine development.
• Clinical trials in Japan are progressing, with results anticipated.
• Further evolution of nanotechnology in nucleic acid medicines is expected.